Page 4 - Essential Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Essential Pharma, an international specialty pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces the closing of two transactions with Rosemont Pharmaceuticals (“Rosemont”). Essential Pharma has completed the ...

- Divestments of UK oral liquid products streamlines the portfolio and furthers Essential Pharma's international growth strategy - Acquired products are low volume, but essential medicines

Essential Pharma Appoints Steen Vangsgaard As Chief Executive Officer News provided by Share this article Share this article EGHAM, England, May 10, 2021 /PRNewswire/ -- Essential Pharma, an international specialty pharma company focused on maintaining access to well-established, "at risk" products essential to patients across multiple therapeutic areas, announces the appointment of Steen Vangsgaard as Chief Executive Officer. Steen has more than 20 years of experience in the specialty pharma and generics sector gained across a wide range of international commercial operations and companies....

Essential Pharma Appoints Pharma and Healthcare Operations Expert Colin Brown As Chief Operating Officer News provided by Share this article Share this article EGHAM, England, Feb. 9, 2021 /PRNewswire/ -- Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, "at risk" products to patients across multiple therapeutic areas, announces the appointment of Colin Brown as Chief Operating Officer. Colin has more than 35 years of experience in the pharmaceutical and consumer healthcare sectors, primarily focused on pharmaceutical development. In a...

CMA secures affordable supply of key bipolar drug The CMA has accepted legally binding commitments from Essential Pharma to continue supplying a key bipolar drug at an affordable price for at least 5 years. From: 18 December 2020 In October, the CMA launched an investigation suspecting that the pharmaceutical supplier, Essential Pharma, may have abused a dominant market position by adopting a strategy to withdraw the bipolar drug, Priadel, from UK patients. This would have caused disruption for patients and doctors, as patients would have been required to switch to alternative, more expen...